MRI Guided Radiotherapy and Radiobiological Data: the ISRAR Database (Irm Sequences for Radiobiological Adaptative Radiotherapy)
Condition: Prostate Cancer, Glioblastoma, Head and Neck Cancer, Kidney Cancer, Cervix Cancer Intervention: Other: 3 MRI sequences (T2*, IVIM and Multi Echo-Gradient), without injection, are performed Sponsor: Hospices Civils de Lyon Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 18, 2023 Category: Research Source Type: clinical trials
A Diagnostic Nomogram for Predicting Vaginal Invasion in Cervical Cancer
Condition: Cervix Carcinoma Intervention: Other: no intervention Sponsor: Fujian Cancer Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials
Nimotuzumab Plus Tislelizumab for Recurrent and Metastatic Cervical Cancer
Condition: Cervical Cancer Intervention: Drug: Nimotuzumab、Tislelizumab Sponsor: Peking Union Medical College Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials
A Diagnostic Nomogram for Predicting Vaginal Invasion in Cervical Cancer
Condition: Cervix Carcinoma Intervention: Other: no intervention Sponsor: Fujian Cancer Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials
Nimotuzumab Plus Tislelizumab for Recurrent and Metastatic Cervical Cancer
Condition: Cervical Cancer Intervention: Drug: Nimotuzumab、Tislelizumab Sponsor: Peking Union Medical College Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials
A Diagnostic Nomogram for Predicting Vaginal Invasion in Cervical Cancer
Condition: Cervix Carcinoma Intervention: Other: no intervention Sponsor: Fujian Cancer Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials
Nimotuzumab Plus Tislelizumab for Recurrent and Metastatic Cervical Cancer
Condition: Cervical Cancer Intervention: Drug: Nimotuzumab、Tislelizumab Sponsor: Peking Union Medical College Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials
A Diagnostic Nomogram for Predicting Vaginal Invasion in Cervical Cancer
Condition: Cervix Carcinoma Intervention: Other: no intervention Sponsor: Fujian Cancer Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials
Nimotuzumab Plus Tislelizumab for Recurrent and Metastatic Cervical Cancer
Condition: Cervical Cancer Intervention: Drug: Nimotuzumab、Tislelizumab Sponsor: Peking Union Medical College Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials
A Diagnostic Nomogram for Predicting Vaginal Invasion in Cervical Cancer
Condition: Cervix Carcinoma Intervention: Other: no intervention Sponsor: Fujian Cancer Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials
Nimotuzumab Plus Tislelizumab for Recurrent and Metastatic Cervical Cancer
Condition: Cervical Cancer Intervention: Drug: Nimotuzumab、Tislelizumab Sponsor: Peking Union Medical College Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials
A Diagnostic Nomogram for Predicting Vaginal Invasion in Cervical Cancer
Condition: Cervix Carcinoma Intervention: Other: no intervention Sponsor: Fujian Cancer Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials
